Chemical, biochemical, and structural similarities and differences of dermatological cAMP phosphodiesterase-IV inhibitors
Wang J, Ho M, Bunick C. Chemical, biochemical, and structural similarities and differences of dermatological cAMP phosphodiesterase-IV inhibitors. Journal Of Investigative Dermatology 2024 PMID: 39608668, DOI: 10.1016/j.jid.2024.10.597.Peer-Reviewed Original ResearchTreatment of psoriasisTopical treatmentAtopic dermatitisTopical treatment of atopic dermatitisIncreased cellular cAMP concentrationOral treatment of psoriasisPDE4 inhibitorsTopical treatment of psoriasisTreatment of atopic dermatitisCellular cAMP concentrationAnti-inflammatory effectsPhosphodiesterase-IV inhibitorImmune cellsOral treatmentPDE4 inhibitionSeborrheic dermatitisInflammatory responseCAMP concentrationAdenosine monophosphateRoflumilastDuration of cAMP signalingPDE4CAMP signalingDermatitisApremilast640 - Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis
Bunick C, Bhatia N, Del Rosso J, Draelos Z, Eichenfield L, Kircik L, Lebwohl M, Gooderham M, Green L, Hebert A, Vender R, Zirwas M, Simpson E, Gold L, Seal M, Snyder S, Osborne D, Burnett P, Higham R, Chu D, Berk D. 640 - Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis. British Journal Of Dermatology 2024, 191: ljae266.021. DOI: 10.1093/bjd/ljae266.021.Peer-Reviewed Original ResearchPhase 3 trialLocal tolerancePatient treatment adherenceAdverse eventsAtopic dermatitisSeborrheic dermatitisPenetration enhancersRoflumilast-treated patientsRate of adverse eventsTreatment adherencePatient-rated assessmentsApplication siteTopical medicationsIntertriginous areasRoflumilast creamDay 1Water-based creamRoflumilastInvestigational productPatientsInvestigator-PsoriasisDermatitisPrescription productsTrials504 - Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis
Bunick C, Bhatia N, Del Rosso J, Draelos Z, Eichenfield L, Kircik L, Lebwohl M, Gooderham M, Green L, Hebert A, Vender R, Zirwas M, Simpson E, Gold L, Seal M, Snyder S, Osborne D, Burnett P, Higham R, Chu D, Berk D. 504 - Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis. British Journal Of Dermatology 2024, 190: ii9-ii10. DOI: 10.1093/bjd/ljad498.012.Peer-Reviewed Original ResearchPhase 3 trialLocal tolerancePatient treatment adherenceAdverse eventsPenetration enhancersRoflumilast-treated patientsRate of adverse eventsTreatment adherencePatient-rated assessmentsApplication siteTopical medicationsIntertriginous areasAtopic dermatitisRoflumilast creamDay 1Seborrheic dermatitisWater-based creamRoflumilastInvestigational productPatientsInvestigator-PsoriasisPrescription productsTrialsClinicInvestigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis
Bunick C, Bhatia N, Del Rosso J, Draelos Z, Eichenfield L, Kircik L, Lebwohl M, Gooderham M, Green L, Hebert A, Vender R, Zirwas M, Simpson E, Stein Gold L, Seal M, Snyder S, Osborne D, Burnett P, Higham R, Chu D, Berk D. Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis. SKIN The Journal Of Cutaneous Medicine 2024, 8: s309. DOI: 10.25251/skin.8.supp.309.Peer-Reviewed Original ResearchPhase 3 trialLocal toleranceAdverse eventsPatient treatment adherencePatients discontinued due to adverse eventsAtopic dermatitisSeborrheic dermatitisPenetration enhancersRoflumilast-treated patientsRate of adverse eventsTreatment adherencePatient-rated assessmentsApplication siteTopical medicationsIntertriginous areasRoflumilast creamDay 1RoflumilastWater-based creamInvestigator-Investigational productPatientsPsoriasisDermatitisPrescription products